Close Menu

NEW YORK – MapKure announced a partnership with Personalis on Monday to use its NGS assay, the NeXT Platform, to screen patients for a Phase I clinical trial of its BRAF inhibitor, BGB-3245.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Apr
29
Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.